

Drug Utilization Review Board

Meeting Minutes

Thursday, January 10, 2019
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Kumar Shah, MSc, PEng, Board Chair
Aesha Drozdowski, PharmD
Susan Siegfroid, MD
Eric Cannon, PharmD, FAMCP
Kyle Kitchen, PharmD

Jennifer Brinton, MD
Neal Catalano, PharmD
Katherine Smith, PharmD
Sharon Weinstein, MD

Dept. of Health/Div. of Health Care Financing Staff Present:

Jennifer Strohecker, PharmD, Pharmacy
Director
Bryan Larson, PharmD
Joe Busby, RPh, MBA

Merelynn Berrett, RN
Heather Santacruz, RN
Craig Hummel, MD

University of Utah Drug Regimen Review Center Staff Presenter:

Elena Martinez

Other Individuals Present:

Samantha Cicero, Neurocrine
Rhonda Clark, Indivior
Kent Douglas, Neurocrine
Deron Grothe, Teva
Dale Grant, Neurocrine
Joanne LaFleur, U of U
Lauren Heath, U of U

Jason Bott, Lilly
Lori Howarth, Bayer
Rick Kegler, Otsuka
Jeff Mussack, Otsuka
Valerie Gonzales, U of U
Randi Lewandowski, EMD Serono

Meeting conducted by: Board Chair

1. **Welcome & Housekeeping:** Kumar Shah opened the meeting and reminded everyone to sign the rosters.
2. **Review and Approval of December Minutes:** Susan Siegfroid made a motion to Approve the minutes from December. Aesha Drozdowski seconded the motion. Four in favor, Neal Catalano abstained, motion passed. Katherine Smith, Kyle Kitchen, Eric Cannon, and Sharon Weinstein were not present for this vote.
3. **Pharmacy and Therapeutics Committee Report:** Bryan Larson reported that no P&T Committee meeting was held in November and that the next meeting will be held in March. He also noted that the annual PDL updates were published and are now available.

4. **VMAT-2 Inhibitors:**

a. **Information:**

1. Elena Martinez presented peer reviewed research and guidelines regarding the use of VMAT-2 inhibitors in the treatment of Huntington disease and tardive dyskinesia.

b. **Public Comment**

1. Samantha Cicero from Neurocrine Biosciences presented information pertaining to Ingrezza.

c. **Board Action**

1. **Motion:**

1. Do not place a prior authorization on VMAT-2 inhibitors at this time
2. Reevaluate in 6-12 months
3. Motion to approve: Susan Siegfried. Second: Eric Cannon. All in favor, motion passed.

5. **Public Meeting Adjourned:** Aesha Drozdowski motioned to close the meeting. Kyle Kitchen seconded the motion. Unanimous Approval.

6. **The next meeting scheduled for Thursday, February 14, 2019:** Agents for psoriasis, atopic dermatitis.

Audio recordings of DUR meetings are available online at:
<https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/>